Marc de Garidel
Marc de Garidel | |
|---|---|
| Born | 1956 (age 67–68) Aix-en-Provence, France |
| Education | École Spéciale des Travaux Publics Thunderbird School of Global Management Harvard Business School |
| Occupation | Businessman |
| Known for | Former CEO, Ipsen (2010-16) |
| Title | CEO and Interim Board Chair Abivax |
| Term | 2016- |
| Honours |  Knight Legion of Honour (2008) |
Marc de Garidel is a French businessman.[1] He is the non-executive chairman of the pharmaceutical company Ipsen and advises Mayroy, the Ipsen controlling holding company.[1][2][3][4][5]
Education
Marc de Garidel graduated from the École Spéciale des Travaux Publics, an engineering grandes écoles in Paris.[1][3][4] He received a business degree from the Thunderbird School of Global Management in Glendale, Arizona, US and an executive MBA from Harvard Business School in Boston, Massachusetts.[1][3][4]
Career
In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany.[1][3]
In 1995, he joined Amgen as vice president of finance and treasury for Europe.[1][3][4] In 1998, he became vice president, corporate controller and chief accounting officer of Amgen.[1][3] In 2000, he became vice president and general manager for France, in charge of Amgen France.[1][3] In 2006, he became vice president for Southwestern Europe, including France, Spain, Belgium and Portugal.[1][3] From 2007 to 2010, he served as vice president for Southern Europe, the Middle East, Asia and Latin America at Amgen.[1][3][4]
He was chairman and chief executive officer of Ipsen from November 2010 to July 2016.[1][3][4][5]
He was also president and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.[5]
Effective July 2016, de Garidel has assumed the role of Ipsen non-executive chairman and has continued to sit on the board of directors. In addition, de Garidel will advise Mayroy, the Ipsen controlling holding company.[6] Previously, he was a director of several biotechnology companies, including vice-chairman of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the board since 2015.
In early 2018, de Garidel joined Corvidia Therapeutics, a biotech company based in Waltham, Massachusetts. In April 2018, he raised a 60M series B round led by Venrock & other top tier US & Europe venture capital funds. In June 2020, after its lead asset, Ziltivekimab, was near completion of its phase 2b program, the company was acquired for $2.1B including an upfront of $725M by Novo Nordisk in one of the largest transaction of the biotech sector in the midst of the COVID-19 epidemic.[7]
De Garidel is a director of Claris Biotherapeutics since July 2020. He joined AZTherapies as chief executive officer and board member in October 2020.[8]
Honours
France: Knight of the Legion of Honour (2008)[9]
Bibliography
- La Société du Médicament (2006)
References
- ^ a b c d e f g h i j k "Marc M.P. de Garidel: Executive Profile & Biography". Bloomberg. Retrieved 4 November 2016.
- ^ "(David Meek new CEO of Ipsen)" (PDF). Archived from the original (PDF) on 2016-09-23.
- ^ a b c d e f g h i j "Ipsen biography". Archived from the original on 2013-04-11.
- ^ a b c d e f "Management". Promethera Biosciences. Board of Directors & and (sic) founders. Archived from the original on 11 October 2014.
- ^ a b c "Les membres du G5 santé" [The G5 Health] (in French). G5 Health.
- ^ "David Meek appointed as Chief Executive Officer of Ipsen" (Press release). Ipsen. 11 July 2016 – via Business Wire.
- ^ "CEO spotlight: CinCor's Marc de Garidel — Sofinnova Partners". sofinnovapartners.com. 2022-04-06. Retrieved 2022-12-13.
- ^ "AZTherapies - Harnessing the Power of Neuro-Immunology - Marc de Garidel". AZTherapies. Retrieved 2022-12-13.
- ^ "Ordre de la Légion d'honneur - Nominations, promotions et élévations du 11-07-2008". www.france-phaleristique.com. Retrieved 2022-12-13.